Showing results (311-320 of 346) with videos related to

Sort By:
Pageof 35
Transplantation and Cellular Therapy|September 19, 2021
Bone Marrow versus Peripheral Blood Grafts for Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation CyclophosphamideRohtesh S Mehta, Rima M Saliba, Leonard C Alsfeld, et al.
Bone Marrow Transplantation|May 6, 2022
KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myelomaMahmoud R Gaballa, Junsheng Ma, Mikael Rauf, et al.
The Lancet. Haematology|November 4, 2018
Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trialUday R Popat, Rohtesh S Mehta, Roland Bassett, et al.
The New England Journal of Medicine|December 14, 2012
Cord-blood engraftment with ex vivo mesenchymal-cell cocultureMarcos de Lima, Ian McNiece, Simon N Robinson, et al.
Transplantation and Cellular Therapy|June 12, 2026
Randomized trial of two fractionation schedules of myeloablative busulfan with fludarabine and cladribine in AML or MDSUday R Popat, Konstantinos Lontos, Roland Bassett, et al.
Cell Reports. Medicine|November 17, 2022
A polyamine-centric, blood-based metabolite panel predictive of poor response to CAR-T cell therapy in large B cell lymphomaJohannes F Fahrmann, Neeraj Y Saini, Chang Chia-Chi, et al.
Blood|February 3, 2021
Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphomaPaolo Strati, Sairah Ahmed, Fateeha Furqan, et al.
Blood Advances|August 22, 2020
Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphomaPaolo Strati, Loretta J Nastoupil, Jason Westin, et al.
Cytotherapy|December 15, 2025
Ex vivo mesenchymal progenitor cell-based cord blood cell expansion and exofucosylation to enhance transplant engraftmentPortia Smallbone, Mayela Mendt, Robert Sackstein, et al.
The Lancet. Haematology|June 27, 2020
Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trialElias Jabbour, Guillaume Richard-Carpentier, Yuya Sasaki, et al.
Pageof 35